SSC Subcommittee Program, Sunday 23 May
Control of Anticoagulation, Session 1
Chairman: Trevor Baglin (UK)
Co-chairmen: Walter Ageno (IT), Job Harenberg (DE), Clive Kearon (CA), John Olson (US), Gualtiero Palareti (IT), Sam Schulman (CA), Antonius Van Den Besselaar (NL)
|
Revision of WHO Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy |
14.30 |
|
REGISTRY: Recurrent venous thromboembolism in anticoagulated patients with cancer |
14:50 |
|
Reporting Prothrombin Time Results as International Normalised Ratios for Patients with Chronic Liver Disease |
15:00 |
|
UK NEQAS Anticoagulant dosing exercise |
15:30 |
|
Intra-individual variation of INR and analytical quality requirements |
15:50 |
|
The influence of the direct f Xa inhibitor rivaroxaban on thrombin generation assays in patients with thrombophilia |
16:10 |
|
Thromboprophylaxis after knee arthroscopy and lower leg immobilization with LMWH - monitoring and endpoints |
16:20 |
|
Rivaroaxaban and apixaban - age, weight, gender and renal function on rivaroxaban pharmacokinetics |
16:40 |
| A working party to delineate methodology/endpoints/harmonization of present and future studies on perioperative AC management and bridging therapy Alex Spyropoulos (CA) |
17:10 |
Chairman: Colin Longstaff (UK)
Co-chairmen: Carl-Erik Dempfle (DE), Ann Gils (BE), Dirk Hendriks (BE), Osamu Matsuo (JP), Michael Nesheim (CA), Tetsumei Urano (JP)
|
WHO International Standards |
|
|
The WHO 2nd International Standard for Streptodornase Calibration of tPA antigen in the SSC/ISTH secondary plasma standard lot 3 and lot 4? Update on standardising PAI-1 antigen measurements in plasma |
14.30 |
|
Program to replace the WHO International Standard for Urokinase and other serine proteases |
14.45 |
|
TAFI/CPU |
|
|
PAI-1 and TAFI measurements on samples from inflammatory bowel disease patients |
15.00 |
|
Applying functional TAFIa (CPU) assays to samples from hemophiliacs |
15.20 |
|
Comparative study on proCPU/TAFI assays |
15.40 |
|
Coffee break |
16.00 |
|
Methods |
|
|
Global Fibrinolysis Assays |
16.20 |
|
Comparison of methods used to study Fibrinolysis |
16.40 |
|
D-dimer |
|
|
Update on the NEQAS EQA for D-dimer |
17.00 |
|
Production and analysis of fibrin degradation products |
17.15 |
|
Plans for a collaborative study to prepare a reference preparation for D-dimer |
17.35 |
|
AOB, General discussion |
17.50 |
Chairman: Herbert C Whinna (US)
Co-chairmen: Francesco Bernardi (IT), Elaine Gray (UK), Tilman Hackeng (NL), Steven Kitchen (UK), Richard Marlar (US), P Meijer (NL), Laurent Mosnier (US)
Inconsistencies in protein C assay sensitivity to protein C defects
Peter Cooper (UK)
Variation in protein S activity measurement in clinical samples between different methods
Ian Jennings (UK)
Collaborative study on the establishment of the 3rd International Standard for Antithrombin, Plasma
Elaine Gray (UK)
Availability of reference plasmas for thrombin generation tests
Elaine Gray (UK)
Report from Working Party on Thrombin Generation Tests
Chairman: Françoise Dignat George (FR)
Co-chairmen: Michael Berndt (IE), Jean-Marie Freyssinet (FR), John Griffin (US), Peter Newman (US)
|
Shed proteins/receptors |
|
|
Basic mechanisms regulating receptor shedding. |
14:30 |
|
Soluble GPVI as a clinical biomarker |
14:50 |
|
Soluble CD146 displays angiogenic properties in vivo |
15:10 |
|
Characterization of circulating endothelial cells and progenitors |
|
|
Application of Polychromatic Flow Cytometry to Identify Circulating Mature Endothelial and Endothelial Progenitor Cells with Colony Forming Potential |
15:30 |
|
Limits and advantages of direct flow cytometry for circulating endothelial cell detection |
15:50 |
|
Multifaceted circulating endothelial cells |
16:10 |
|
Determination and characterization of (circulating) microparticles |
|
|
Pre-analytical variables for plasma MP TF activity determination |
16:30 |
|
Analysis of pre-analytical variables for circulating MP enumeration |
16:50 |
|
Advances in nanocytometry |
17:10 |
|
A survey of last generation FCM performances |
17:30 |
|
Advances in impedance-based Flow Cytometry |
17:50 |
|
Correlation between capture assay and flow cytometry in microparticle determination |
18:10 |
Chairman: Jeroen Eikenboom (NL)
Co-chairmen: Thomas Abshire (US), Imre Bodo (HU), Giancarlo Castaman (IT), Jorge DiPaola (US), Emmanuel J Favaloro (AU), Anne Goodeve (UK), Bernhard Lämmle (CH), David Lillicrap (CA), Reinhard Schneppenheim (DE)
|
Standardized Bleeding Scores. Joint session with the following subcommittees: Perinatal/Pediatric Hemostasis Factor VIII & Factor IX Women’s Health Issues in Thrombosis and Haemostasis Platelet Physiology Chairmen: Thomas Abshire (USA)/David Lillicrap (CA) |
|
|
Introduction |
14:30 |
|
Bleeding scores: adult |
14:35 |
|
Bleeding score: pediatric |
14:50 |
|
Bleeding scores: rare bleeding disorders |
15:10 |
|
Bleeding scores: women’s health |
15:30 |
|
Working party for standardized bleeding score: "new" bleeding assessment tool |
15:50 |
|
Discussion |
16:10 |
|
Coffee break |
|
|
VWF assays for VWD diagnosis |
|
|
Alternative assays for GPIb binding, update Hans Deckmyn (BE) Bob Montgomery (US) Reinhard Schneppenheim (DE) |
16:50 17:00 17:10 |
|
Collagen binding assay, current status |
17:20 |
|
Flow based assays Keith Neeves (US) |
17:40 |
|
Discussion |
17:50 |
|
VWF propeptide studies |
|
|
Working party on standardization of VWFpp assays |
18:00 |
|
Discussion |
18:10 |
|
VWF plasma and concentrate standards |
|
|
WHO 2nd international standard VWF concentrate |
18:20 |